|

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

RECRUITINGSponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Actively Recruiting
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Started2025-02-04
Est. completion2044-08-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06794268

Summary

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

• Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA

Exclusion Criteria:

* Participants known to be participating in investigational studies at the time of liso-cel, infusion
* Participants treated with liso-cel for the treatment of R/R FL Grade 3b
* Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product

Conditions2

CancerFollicular Lymphoma

Locations1 site

CIBMTR
Milwaukee, Wisconsin, 53226

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.